- Previous Close
160.04 - Open
0.00 - Bid --
- Ask --
- Day's Range
0.00 - 0.00 - 52 Week Range
0.00 - 185.00 - Volume
0 - Avg. Volume
87 - Market Cap (intraday)
73.14B - Beta (5Y Monthly) 0.89
- PE Ratio (TTM)
32.87 - EPS (TTM)
4.90 - Earnings Date Nov 4, 2024
- Forward Dividend & Yield 1.59 (0.99%)
- Ex-Dividend Date Oct 31, 2024
- 1y Target Est
--
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.
www.zoetis.com14,100
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: ZOE.DE
View MorePerformance Overview: ZOE.DE
Trailing total returns as of 11/5/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ZOE.DE
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ZOE.DE
View MoreValuation Measures
Market Cap
72.99B
Enterprise Value
77.63B
Trailing P/E
32.71
Forward P/E
27.86
PEG Ratio (5yr expected)
2.47
Price/Sales (ttm)
8.69
Price/Book (mrq)
15.06
Enterprise Value/Revenue
9.67
Enterprise Value/EBITDA
23.72
Financial Highlights
Profitability and Income Statement
Profit Margin
26.55%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
9.15B
Net Income Avi to Common (ttm)
2.43B
Diluted EPS (ttm)
4.90
Balance Sheet and Cash Flow
Total Cash (mrq)
1.57B
Total Debt/Equity (mrq)
136.57%
Levered Free Cash Flow (ttm)
--